Drug shortages
Supply-availability records maintained by the FDA Drug Shortages program. A record tracks whether a specific presentation is available, limited, or unavailable, and the reason the manufacturer gave. Shortages are common and often resolve; always confirm current supply with a dispensing pharmacy.
1,601 records · 1,153 current · source: FDA Drug Shortages
| Status | Availability | Generic name | Presentation | Company | Updated |
|---|---|---|---|---|---|
| To Be Discontinued | Somatropin Injection | Norditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21) | Novo Nordisk, Inc. | November 14, 2025 | |
| To Be Discontinued | Ceftazidime Injection | Tazicef, Injection, 2 g (NDC 0409-5093-11) | Hospira, Inc., a Pfizer Company | November 14, 2025 | |
| To Be Discontinued | Vancomycin Hydrochloride Injection | Vancomycin Hydrochloride, Injection, 10 g Vial NovaPlus (NDC 0409-5017-01) | Hospira, Inc., a Pfizer Company | November 14, 2025 | |
| To Be Discontinued | Palonosetron Hydrochloride Injection | Palonosetron Hydrochloride, Injection, .25 mg/5 mL (NDC 0703-4094-01) | Teva Pharmaceuticals USA, Inc. | November 14, 2025 | |
| To Be Discontinued | Ceftazidime Injection | Tazicef, Injection, 1 g (NDC 0409-5092-16) | Hospira, Inc., a Pfizer Company | November 14, 2025 | |
| To Be Discontinued | Guanfacine Hydrochloride Tablet, Extended Release | Guanfacine Hydrochloride, Tablet, Extended Release, 4 mg (NDC 0228-2855-11) | Actavis Pharma, Inc. | November 13, 2025 | |
| To Be Discontinued | Adalimumab-ryvk Kit | Simlandi, Kit, Kit (NDC 51759-523-21) | Teva Pharmaceuticals USA, Inc. | November 13, 2025 | |
| To Be Discontinued | Guanfacine Hydrochloride Tablet, Extended Release | Guanfacine Hydrochloride, Tablet, Extended Release, 1 mg (NDC 0228-2850-11) | Actavis Pharma, Inc. | November 13, 2025 | |
| To Be Discontinued | Guanfacine Hydrochloride Tablet, Extended Release | Guanfacine Hydrochloride, Tablet, Extended Release, 2 mg (NDC 0228-2851-11) | Actavis Pharma, Inc. | November 13, 2025 | |
| To Be Discontinued | Guanfacine Hydrochloride Tablet, Extended Release | Guanfacine Hydrochloride, Tablet, Extended Release, 3 mg (NDC 0228-2853-11) | Actavis Pharma, Inc. | November 13, 2025 | |
| To Be Discontinued | Cetrorelix Acetate Injection | Cetrorelix Acetate, Injection, Kit (NDC 0480-5795-08) | Teva Pharmaceuticals USA, Inc. | November 13, 2025 | |
| To Be Discontinued | Frovatriptan Succinate Tablet | Frova, Tablet, 2.5 mg (NDC 0603-3718-34) | Endo Pharmaceuticals, Inc. | November 12, 2025 | |
| To Be Discontinued | Sodium Bicarbonate Injection | Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 0409-6637-14) | Hospira, Inc., a Pfizer Company | November 7, 2025 | |
| To Be Discontinued | Ketamine Hydrochloride Injection | Ketamine Hydrochloride, Injection, 500 mg/5mL (100 mg/mL); Multiple Dose Glass Fliptop… | Pfizer Inc. | November 7, 2025 | |
| To Be Discontinued | Sodium Bicarbonate Injection | Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 0409-4900-14) | Hospira, Inc., a Pfizer Company | November 7, 2025 | |
| To Be Discontinued | Atropine Sulfate Injection | Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass… | Hospira, Inc., a Pfizer Company | November 7, 2025 | |
| To Be Discontinued | Atropine Sulfate Injection | Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass… | Hospira, Inc., a Pfizer Company | November 7, 2025 | |
| To Be Discontinued | Dextrose Monohydrate 50% Injection | Dextrose Monohydrate 50%, Injection, 50% Dextrose Injection 0.5 g/mL; ABBOJECT® Glass… | Hospira, Inc., a Pfizer Company | November 7, 2025 | |
| To Be Discontinued | Deferiprone Tablet | Ferriprox, Tablet, 500 mg (NDC 10122-100-10) | Chiesi USA, Inc. | November 7, 2025 | |
| To Be Discontinued | Sodium Bicarbonate Injection | Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 0409-5534-14) | Hospira, Inc., a Pfizer Company | November 7, 2025 | |
| To Be Discontinued | Sodium Bicarbonate Injection | Sodium Bicarbonate, Injection, 75 mg/1 mL (NDC 0409-4916-14) | Hospira, Inc., a Pfizer Company | November 7, 2025 | |
| To Be Discontinued | Epinephrine Injection | Epinephrine, Injection, .1 mg/1 mL (NDC 0409-4933-01) | Hospira, Inc., a Pfizer Company | November 7, 2025 | |
| To Be Discontinued | Epinephrine Injection | Epinephrine, Injection, .1 mg/1 mL (NDC 0409-4933-10) | Hospira, Inc., a Pfizer Company | November 7, 2025 | |
| To Be Discontinued | Lidocaine Hydrochloride Injection | Lidocaine Hydrochloride, Injection, 1%, USP (For Cardiac Use Only) 50 mg/5 mL (10 mg/mL)… | Hospira, Inc., a Pfizer Company | November 7, 2025 | |
| To Be Discontinued | Lidocaine Hydrochloride Injection | Lidocaine Hydrochloride, Injection, 2%, USP (For Cardiac Use Only) 100 mg/5 mL (20 mg/mL)… | Hospira, Inc., a Pfizer Company | November 7, 2025 | |
| To Be Discontinued | Calcium Chloride Injection | Calcium Chloride, Injection, 100 mg/1 mL (NDC 0409-4928-34) | Hospira, Inc., a Pfizer Company | November 7, 2025 | |
| To Be Discontinued | Everolimus Tablet | Everolimus, Tablet, 3 mg (NDC 0378-0006-85) | Mylan Pharmaceuticals Inc., a Viatris Company | November 3, 2025 | |
| To Be Discontinued | Scopolamine Transdermal System | Scopolamine, Transdermal System, 1 mg (NDC 45802-580-46) | Padagis US LLC | November 3, 2025 | |
| To Be Discontinued | Acetaminophen; Oxycodone Hydrochloride Tablet | Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 5 mg (NDC 60951-602-70) | Endo Pharmaceuticals, Inc. | November 3, 2025 | |
| To Be Discontinued | Lasmiditan Succinate Tablet | Reyvow, Tablet, 100 mg (NDC 0002-4491-08) | Eli Lilly and Co. | November 3, 2025 | |
| To Be Discontinued | Everolimus Tablet | Everolimus, Tablet, 2 mg (NDC 0378-0005-85) | Mylan Pharmaceuticals Inc., a Viatris Company | November 3, 2025 | |
| To Be Discontinued | Atazanavir Sulfate; Cobicistat Tablet | Evotaz, Tablet, 300 mg; 150 mg (NDC 0003-3641-11) | Bristol Myers Squibb Co. | November 3, 2025 | |
| To Be Discontinued | Acetaminophen; Oxycodone Hydrochloride Tablet | Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 5 mg (NDC 60951-602-85) | Endo Pharmaceuticals, Inc. | November 3, 2025 | |
| To Be Discontinued | Lasmiditan Succinate Tablet | Reyvow, Tablet, 100 mg (NDC 0002-4491-61) | Eli Lilly and Co. | November 3, 2025 | |
| To Be Discontinued | Everolimus Tablet | Everolimus, Tablet, 5 mg (NDC 0378-0007-85) | Mylan Pharmaceuticals Inc., a Viatris Company | November 3, 2025 | |
| To Be Discontinued | Lasmiditan Succinate Tablet | Reyvow, Tablet, 50 mg (NDC 0002-4312-61) | Eli Lilly and Co. | November 3, 2025 | |
| To Be Discontinued | Acetaminophen; Oxycodone Hydrochloride Tablet | Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 2.5 mg (NDC 60951-701-70) | Endo Pharmaceuticals, Inc. | November 3, 2025 | |
| To Be Discontinued | Acetaminophen; Oxycodone Hydrochloride Tablet | Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 10 mg (NDC 60951-712-70) | Endo Pharmaceuticals, Inc. | November 3, 2025 | |
| To Be Discontinued | Lasmiditan Succinate Tablet | Reyvow, Tablet, 50 mg (NDC 0002-4312-62) | Eli Lilly and Co. | November 3, 2025 | |
| To Be Discontinued | Acetaminophen; Oxycodone Hydrochloride Tablet | Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 7.5 mg (NDC 60951-700-70) | Endo Pharmaceuticals, Inc. | November 3, 2025 | |
| To Be Discontinued | Lasmiditan Succinate Tablet | Reyvow, Tablet, 100 mg (NDC 0002-4491-62) | Eli Lilly and Co. | November 3, 2025 | |
| To Be Discontinued | Lasmiditan Succinate Tablet | Reyvow, Tablet, 50 mg (NDC 0002-4312-08) | Eli Lilly and Co. | November 3, 2025 | |
| To Be Discontinued | Acetaminophen; Oxycodone Hydrochloride Tablet | Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 2.5 mg (NDC 63481-627-70) | Endo Pharmaceuticals, Inc. | November 3, 2025 | |
| To Be Discontinued | Phenobarbital Tablet | Phenobarbital, Tablet, 16.2 mg (NDC 0603-5165-32) | Endo Pharmaceuticals, Inc. | October 31, 2025 | |
| To Be Discontinued | Phenobarbital Tablet | Phenobarbital, Tablet, 32.4 mg (NDC 0603-5166-21) | Endo Pharmaceuticals, Inc. | October 31, 2025 | |
| To Be Discontinued | Phenobarbital Tablet | Phenobarbital, Tablet, 97.2 mg (NDC 0603-5168-32) | Endo Pharmaceuticals, Inc. | October 31, 2025 | |
| To Be Discontinued | Phenobarbital Tablet | Phenobarbital, Tablet, 32.4 mg (NDC 0603-5166-32) | Endo Pharmaceuticals, Inc. | October 31, 2025 | |
| To Be Discontinued | Phenobarbital Tablet | Phenobarbital, Tablet, 97.2 mg (NDC 0603-5168-21) | Endo Pharmaceuticals, Inc. | October 31, 2025 | |
| To Be Discontinued | Phenobarbital Tablet | Phenobarbital, Tablet, 64.8 mg (NDC 0603-5167-21) | Endo Pharmaceuticals, Inc. | October 31, 2025 | |
| To Be Discontinued | Phenobarbital Tablet | Phenobarbital, Tablet, 16.2 mg (NDC 0603-5165-21) | Endo Pharmaceuticals, Inc. | October 31, 2025 | |
| To Be Discontinued | Phenobarbital Tablet | Phenobarbital, Tablet, 64.8 mg (NDC 0603-5167-32) | Endo Pharmaceuticals, Inc. | October 31, 2025 | |
| To Be Discontinued | Moxifloxacin Injection | Moxifloxacin, Injection, 400mg per 250mL (NDC 63323-850-74) | Fresenius Kabi USA, LLC | October 29, 2025 | |
| To Be Discontinued | Pramlintide Acetate Injection | SymlinPen® 60 , Injection, 1000 ug/1 mL (NDC 0310-6615-02) | AstraZeneca AB | October 27, 2025 | |
| To Be Discontinued | Pramlintide Acetate Injection | SymlinPen® 120 , Injection, 1000 ug/1 mL (NDC 0310-6627-02) | AstraZeneca AB | October 27, 2025 | |
| To Be Discontinued | Busulfan Injection | Busulfan, Injection, 6 mg/1 mL (NDC 67457-893-08) | Mylan Institutional, a Viatris Company | October 24, 2025 | |
| To Be Discontinued | Insulin Lispro-aabc Injection | Lyumjev, Injection, U-100 Tempo Pen Sample (NDC 0002-8235-99) | Eli Lilly and Co. | October 24, 2025 | |
| To Be Discontinued | Insulin Glargine Injection | Basaglar, Injection, U-100 Tempo Pen (NDC 0002-8214-05) | Eli Lilly and Co. | October 24, 2025 | |
| To Be Discontinued | Insulin Lispro Injection | Humalog, Injection, U-100 Tempo Pen (NDC 0002-8213-05) | Eli Lilly and Co. | October 24, 2025 | |
| To Be Discontinued | Insulin Lispro-aabc Injection | Lyumjev, Injection, U-100 Tempo Pen (NDC 0002-8235-05) | Eli Lilly and Co. | October 24, 2025 | |
| To Be Discontinued | Tranylcypromine Sulfate Tablet | Parnate, Tablet, 10 mg (NDC 0591-5590-01) | Teva Pharmaceuticals USA, Inc. | October 21, 2025 | |
| To Be Discontinued | Oxaliplatin Injection | Oxaliplatin, Injection, 5 mg/1 mL (NDC 0781-3315-70) | Sandoz Inc. | October 20, 2025 | |
| To Be Discontinued | Oxaliplatin Injection | Oxaliplatin, Injection, 5 mg/1 mL (NDC 0781-3317-80) | Sandoz Inc. | October 20, 2025 | |
| To Be Discontinued | Elbasvir; Grazoprevir Tablet | Zepatier, Tablet, 50 mg; 100 mg (NDC 0006-3074-02) | Merck Sharp & Dohme LLC | October 17, 2025 | |
| To Be Discontinued | Voriconazole Injection | Vfend, Injection, 10 mg/1 mL (NDC 0049-3190-01) | Pfizer Inc. | October 16, 2025 | |
| To Be Discontinued | Pemetrexed Disodium Injection | Alimta, Injection, 100 mg/4 mL (NDC 0002-7640-01) | Eli Lilly and Co. | October 16, 2025 | |
| To Be Discontinued | Pemetrexed Disodium Injection | Alimta, Injection, 500 mg/20 mL (NDC 0002-7623-01) | Eli Lilly and Co. | October 16, 2025 | |
| To Be Discontinued | Vigabatrin Oral Solution | Vigpoder, Oral Solution, 50 mg/1 mL (NDC 80789-117-50) | Pyros Pharmaceuticals, Inc. | October 16, 2025 | |
| To Be Discontinued | Pemetrexed Disodium Injection | Pemetrexed Disodium, Injection, 500 mg/20 mL (NDC 0781-3519-90) | Sandoz Inc. | October 10, 2025 | |
| To Be Discontinued | Pemetrexed Disodium Injection | Pemetrexed Disodium, Injection, 100 mg/4 mL (NDC 0781-3518-76) | Sandoz Inc. | October 10, 2025 | |
| To Be Discontinued | Omeprazole Delayed Release Capsule | Omeprazole, Delayed Release Capsule, 10 mg (NDC 0781-2859-31) | Sandoz Inc. | October 9, 2025 | |
| To Be Discontinued | Omeprazole Delayed Release Capsule | Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-10) | Sandoz Inc. | October 9, 2025 | |
| To Be Discontinued | Omeprazole Delayed Release Capsule | Omeprazole, Delayed Release Capsule, 40 mg (NDC 0781-2234-10) | Sandoz Inc. | October 9, 2025 | |
| To Be Discontinued | Adalimumab-afzb Injection | Abrilada, Injection, Kit (NDC 0025-0325-01) | Pfizer Inc. | October 9, 2025 | |
| To Be Discontinued | Omeprazole Delayed Release Capsule | Omeprazole, Delayed Release Capsule, 40 mg (NDC 0781-2234-01) | Sandoz Inc. | October 9, 2025 | |
| To Be Discontinued | Omeprazole Delayed Release Capsule | Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-92) | Sandoz Inc. | October 9, 2025 | |
| To Be Discontinued | Omeprazole Delayed Release Capsule | Omeprazole, Delayed Release Capsule, 40 mg (NDC 0781-2234-31) | Sandoz Inc. | October 9, 2025 | |
| To Be Discontinued | Omeprazole Delayed Release Capsule | Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-01) | Sandoz Inc. | October 9, 2025 | |
| To Be Discontinued | Omeprazole Delayed Release Capsule | Omeprazole, Delayed Release Capsule, 10 mg (NDC 0781-2859-01) | Sandoz Inc. | October 9, 2025 | |
| To Be Discontinued | Omeprazole Delayed Release Capsule | Omeprazole, Delayed Release Capsule, 10 mg (NDC 0781-2859-10) | Sandoz Inc. | October 9, 2025 | |
| To Be Discontinued | Omeprazole Delayed Release Capsule | Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-31) | Sandoz Inc. | October 9, 2025 | |
| To Be Discontinued | Paricalcitol Capsule | Zemplar, Capsule, 2 ug (NDC 0074-9037-30) | AbbVie Inc. | October 7, 2025 | |
| To Be Discontinued | Paricalcitol Capsule | Zemplar, Capsule, 1 ug (NDC 0074-9036-30) | AbbVie Inc. | October 7, 2025 | |
| To Be Discontinued | Cobicistat Tablet | Tybost, Tablet, 150 mg (NDC 61958-1401-1) | Gilead Sciences, Inc. | October 7, 2025 | |
| To Be Discontinued | Hydrochlorothiazide; Quinapril Hydrochloride Tablet | Accuretic, Tablet, 12.5 mg; 10 mg (NDC 0071-3112-23) | Pfizer Inc. | October 1, 2025 | |
| To Be Discontinued | Hydrochlorothiazide; Quinapril Hydrochloride Tablet | Accuretic, Tablet, 12.5 mg; 20 mg (NDC 0071-5212-23) | Pfizer Inc. | October 1, 2025 | |
| To Be Discontinued | Quinapril Hydrochloride Tablet | Accupril, Tablet, 5 mg (NDC 0071-0527-23) | Pfizer Inc. | October 1, 2025 | |
| To Be Discontinued | Quinapril Hydrochloride Tablet | Accupril, Tablet, 10 mg (NDC 0071-0530-23) | Pfizer Inc. | October 1, 2025 | |
| To Be Discontinued | Quinapril Hydrochloride Tablet | Accupril, Tablet, 40 mg (NDC 0071-0535-23) | Pfizer Inc. | October 1, 2025 | |
| To Be Discontinued | Quinapril Hydrochloride Tablet | Accupril, Tablet, 20 mg (NDC 0071-0532-23) | Pfizer Inc. | October 1, 2025 | |
| To Be Discontinued | Oseltamivir Phosphate Capsule | Tamiflu, Capsule, 45 mg (NDC 0004-0801-85) | Genentech, Inc | September 30, 2025 | |
| To Be Discontinued | Triazolam Tablet | Halcion, Tablet, .25 mg (NDC 0009-0017-58) | Pfizer Inc. | September 29, 2025 | |
| To Be Discontinued | Fondaparinux Sodium Injection | Fondaparinux Sodium, Injection, 2.5 mg/.5 mL (NDC 0781-3443-95) | Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) | September 29, 2025 | |
| To Be Discontinued | Fondaparinux Sodium Injection | Fondaparinux Sodium, Injection, 10 mg/.8 mL (NDC 0781-3476-95) | Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) | September 29, 2025 | |
| To Be Discontinued | Fondaparinux Sodium Injection | Fondaparinux Sodium, Injection, 7.5 mg/.6 mL (NDC 0781-3465-95) | Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) | September 29, 2025 | |
| To Be Discontinued | Tafamidis Meglumine Capsule | Vyndaqel, Capsule, 20 mg soft gelatin capsules; blister card (120 total capsules) (NDC… | Pfizer Inc. | September 29, 2025 | |
| To Be Discontinued | Fondaparinux Sodium Injection | Fondaparinux Sodium, Injection, 5 mg/.4 mL (NDC 0781-3454-95) | Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) | September 29, 2025 | |
| To Be Discontinued | Irinotecan Hydrochloride Injection | Irinotecan Hydrochloride, Injection, 100 mg/5 mL (NDC 25021-230-05) | Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) | September 26, 2025 | |
| To Be Discontinued | Irinotecan Hydrochloride Injection | Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 25021-230-02) | Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) | September 26, 2025 | |
| To Be Discontinued | Prazosin Hydrochloride Capsule | Minipress, Capsule, 2 mg (NDC 0069-4370-71) | Pfizer Inc. | April 28, 2023 | |
| To Be Discontinued | Prazosin Hydrochloride Capsule | Minipress, Capsule, 1 mg (NDC 0069-4310-71) | Pfizer Inc. | April 28, 2023 | |
| To Be Discontinued | Prazosin Hydrochloride Capsule | Minipress, Capsule, 5 mg (NDC 0069-4380-71) | Pfizer Inc. | April 28, 2023 |